| Not Yet Recruiting | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy NCT07453095 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Not Yet Recruiting | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard o NCT07341191 | Canadian Cancer Trials Group | Phase 2 |
| Recruiting | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory NCT07377578 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 3 |
| Not Yet Recruiting | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma NCT07207785 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Not Yet Recruiting | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma NCT07261163 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas NCT06300528 | University of Utah | Phase 2 |
| Not Yet Recruiting | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and NCT07206264 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated M NCT07029737 | AstraZeneca | Phase 2 |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MC NCT06357676 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib ( NCT06854003 | Christine Ryan | Phase 2 |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zan NCT06742996 | BeOne Medicines | Phase 3 |
| Recruiting | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465 | Medical College of Wisconsin | Phase 1 |
| Recruiting | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patient NCT06522386 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma NCT06572618 | City of Hope Medical Center | Phase 2 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Recruiting | CD70-targeted immunoPET Imaging of Malignant Cancers NCT06852638 | RenJi Hospital | N/A |
| Recruiting | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT06054776 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutini NCT06656221 | Ruijin Hospital | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Not Yet Recruiting | Patient Perspectives in Mantle Cell Lymphoma Clinical Research NCT06049472 | Power Life Sciences Inc. | — |
| Recruiting | Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL NCT06553872 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diag NCT06504199 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma NCT06252675 | University of California, San Francisco | Phase 2 |
| Recruiting | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle NCT06263491 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL NCT06363994 | InnoCare Pharma Inc. | Phase 3 |
| Recruiting | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lympho NCT06341556 | Fudan University | Phase 2 |
| Recruiting | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma NCT05635162 | University College, London | Phase 2 |
| Recruiting | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma NCT06029309 | Alvaro Alencar, MD | Phase 1 / Phase 2 |
| Not Yet Recruiting | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymph NCT06324994 | Dalian Medical University | Phase 2 |
| Unknown | Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309 | British Columbia Cancer Agency | — |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Not Yet Recruiting | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Di NCT06255704 | Shanxi Province Cancer Hospital | Phase 2 |
| Recruiting | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen R NCT05887167 | Joshua Sasine, MD, PhD | Phase 1 |
| Recruiting | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma NCT06482684 | Christian Schmidt, MD | Phase 2 |
| Completed | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) NCT06004167 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma NCT06192888 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Mali NCT06151730 | Mayo Clinic | — |
| Recruiting | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma NCT05868395 | Medical University of Vienna | Phase 2 |
| Recruiting | Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma NCT05004064 | University College, London | Phase 2 |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Prev NCT05976763 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Recruiting | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Expo NCT05833763 | Australasian Leukaemia and Lymphoma Group | Phase 2 |
| Terminated | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) NCT06106841 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas NCT05934838 | Weill Medical College of Cornell University | Phase 1 |
| Recruiting | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas NCT05365659 | Iksuda Therapeutics Ltd. | Phase 1 |
| Unknown | Evaluating Different Doses of Orelabrutinib in MCL NCT05978739 | InnoCare Pharma Inc. | Phase 2 |
| Recruiting | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed NCT05861050 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Recruiting | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem C NCT05432635 | City of Hope Medical Center | Phase 1 |
| Completed | A Food Effect Study of LP-168 Tablets in Healthy Subjects NCT05917964 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Active Not Recruiting | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062 | Synthekine | Phase 1 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Withdrawn | Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma NCT04231734 | Weill Medical College of Cornell University | N/A |
| Terminated | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma NCT05788289 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax NCT05724121 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Active Not Recruiting | Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Stud NCT04882475 | Fondazione Italiana Linfomi - ETS | — |
| Completed | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and S NCT05694364 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients NCT05529069 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma NCT05934097 | Fate Therapeutics | Phase 1 |
| Terminated | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT05611853 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Pati NCT05495464 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB The NCT05245656 | Kim, Seok Jin | Phase 2 |
| Unknown | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. NCT05888701 | University of Milano Bicocca | — |
| Active Not Recruiting | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma NCT05471843 | BeiGene | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive an NCT05458297 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma NCT05444322 | He Huang | EARLY_Phase 1 |
| Terminated | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma NCT05025423 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354 | Adaptive Biotechnologies | — |
| Unknown | Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma NCT05486013 | Peking University Third Hospital | — |
| Recruiting | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P NCT05294731 | BeiGene | Phase 1 / Phase 2 |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Completed | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy NCT05064787 | Pack Health | N/A |
| Withdrawn | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With New NCT04849715 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma NCT04802590 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies NCT04599634 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma NCT05214183 | Nordic Lymphoma Group | Phase 2 |
| Unknown | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Phase 1 |
| Unknown | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma NCT05076097 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma NCT05020392 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent NCT04883437 | Emory University | Phase 2 |
| Terminated | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Pr NCT04692155 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Recruiting | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With NCT04626791 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Recruiting | Avo In R/R And Previously Untreated MCL NCT04855695 | Austin I Kim | Phase 1 / Phase 2 |
| Active Not Recruiting | Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma NCT04765111 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | B-cell Chronic Lymphoid Malignancies Markers NCT04952974 | University Hospital, Strasbourg, France | — |
| Completed | Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymp NCT04918940 | Centre Henri Becquerel | N/A |
| Unknown | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083 | NovalGen Ltd. | Phase 1 |
| Recruiting | CONFIRM: Magnetic Resonance Guided Radiation Therapy NCT04368702 | Brigham and Women's Hospital | N/A |
| Unknown | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphom NCT05097443 | Shandong Provincial Hospital | Phase 3 |
| Active Not Recruiting | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma NCT04783415 | City of Hope Medical Center | Phase 2 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Terminated | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphom NCT04419389 | Aprea Therapeutics | Phase 1 / Phase 2 |
| Terminated | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies NCT04844086 | Eden BioCell Ltd. | Phase 1 |
| Recruiting | Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma NCT04566887 | University Health Network, Toronto | Phase 2 |
| Unknown | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin NCT05164770 | Shandong Provincial Hospital | Phase 3 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Unknown | Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymp NCT04736914 | Sun Yat-sen University | Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma NCT04718883 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Unknown | Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years NCT05429918 | Peking University Third Hospital | — |
| Active Not Recruiting | Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL NCT04624958 | Sun Yat-sen University | Phase 2 |
| Terminated | Study of LUCAR-20S in Patients With R/R NHL NCT04176913 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Withdrawn | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 NCT04665115 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapse NCT04223765 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Completed | The Role of 18F-FDG-PET for Staging and Prognostication NCT04600804 | Fondazione Italiana Linfomi - ETS | — |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Completed | A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Ha NCT04564040 | AstraZeneca | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Active Not Recruiting | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma NCT04189757 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma NCT04402138 | SCRI Development Innovations, LLC | Phase 2 |
| Withdrawn | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma NCT03617484 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies NCT04279405 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Active Not Recruiting | Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma NCT03282396 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Atrial Fibrillation in Patients Receiving Ibrutinib NCT04407845 | European Georges Pompidou Hospital | — |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab NCT04282018 | BeiGene | Phase 1 / Phase 2 |
| Completed | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia NCT04323657 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies NCT04043845 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) NCT04127916 | Samsung Medical Center | — |
| Completed | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years o NCT03834688 | PrECOG, LLC. | Phase 2 |
| Active Not Recruiting | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lym NCT04115631 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Italian Observational Study on CAR-T Therapy for Lymphoma NCT06339255 | Paolo Corradini | — |
| Completed | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyr NCT04116437 | BeiGene | Phase 2 |
| Active Not Recruiting | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL NCT03863184 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transp NCT03579927 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma NCT04082936 | IGM Biosciences, Inc. | Phase 1 / Phase 2 |
| Unknown | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL NCT03891355 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT NCT04716075 | Polish Lymphoma Research Group | Phase 2 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma NCT04061850 | Samsung Medical Center | — |
| Withdrawn | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Ly NCT03232307 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma NCT03939182 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Active Not Recruiting | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantl NCT03710772 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma NCT03872180 | Emory University | Phase 2 |
| Completed | A Disease Registry of Patients With Mantle Cell Lymphoma NCT03816683 | AstraZeneca | — |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL NCT03740529 | Loxo Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Terminated | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle C NCT03685344 | ADC Therapeutics S.A. | Phase 1 |
| Completed | BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma NCT03836768 | Zhejiang DTRM Biopharma | Phase 1 |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma NCT03523975 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) NCT03616782 | Ho Sup Lee | Phase 2 |
| Terminated | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphom NCT03684694 | ADC Therapeutics S.A. | Phase 1 / Phase 2 |
| Unknown | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies NCT03999697 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Completed | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymph NCT03623373 | Washington University School of Medicine | Phase 2 |
| Terminated | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma NCT03585725 | Weill Medical College of Cornell University | EARLY_Phase 1 |
| Completed | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma NCT04833504 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Unknown | Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRM NCT04109872 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Active Not Recruiting | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma NCT03478514 | Alliance Foundation Trials, LLC. | Phase 2 |
| Recruiting | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-gener NCT03676504 | University Hospital Heidelberg | Phase 1 / Phase 2 |
| Completed | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma NCT03323151 | PrECOG, LLC. | Phase 1 / Phase 2 |
| Terminated | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies NCT03151057 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Ta NCT03010982 | Epizyme, Inc. | Phase 1 |
| Terminated | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse NCT03229382 | Polish Lymphoma Research Group | Phase 2 |
| Completed | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade NCT03410901 | Ronald Levy | Phase 1 |
| Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576 | Emory University | — |
| Unknown | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) NCT03494179 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT03424603 | Sutro Biopharma, Inc. | Phase 1 |
| Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product NCT03436771 | Juno Therapeutics, a Subsidiary of Celgene | — |
| Unknown | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects NCT03629873 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refr NCT04184414 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Completed | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies NCT03088878 | Oncternal Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells NCT03375619 | Medical College of Wisconsin | — |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Active Not Recruiting | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Man NCT03267433 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL NCT03019666 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patient NCT03019640 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma NCT03311126 | University of Wisconsin, Madison | Phase 2 |
| Completed | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma NCT03295240 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom NCT02952508 | Cellectar Biosciences, Inc. | Phase 2 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Active Not Recruiting | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic NCT03153202 | Joshua Brody | Phase 1 / Phase 2 |
| Completed | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas NCT03188965 | Bayer | Phase 1 |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 NCT03162536 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 / Phase 2 |
| Completed | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) NCT03112174 | Pharmacyclics LLC. | Phase 3 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers NCT03037645 | Sunesis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK o NCT03028103 | Epizyme, Inc. | Phase 1 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk NCT02483000 | Fred Hutchinson Cancer Center | Phase 1 |
| Unknown | The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymph NCT03016988 | Tingbo Liu | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Completed | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Mainte NCT02896582 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1 NCT02927964 | Robert Lowsky | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepa NCT02991638 | The University of Hong Kong | Phase 3 |
| Completed | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents NCT02745769 | Eli Lilly and Company | Phase 1 |
| Completed | Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma NCT02840539 | Seoul National University Hospital | Phase 2 |
| Unknown | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma NCT02819583 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia a NCT02892695 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Recruiting | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma NCT02858258 | Prof. Dr. M. Dreyling (co-chairman) | Phase 3 |
| Unknown | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymp NCT02851589 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisi NCT02793583 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Active Not Recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma NCT02339922 | University of Washington | Phase 2 |
| Active Not Recruiting | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL NCT02682641 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Completed | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma NCT02756247 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With NCT02735876 | Acerta Pharma BV | Phase 3 |
| Completed | Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma NCT02728531 | Washington University School of Medicine | Phase 1 |
| Unknown | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission NCT02632396 | Emory University | Phase 1 / Phase 2 |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Completed | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) NCT02631044 | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 |
| Completed | EDOCH Alternating With DHAP for New Diagnosed Younger MCL NCT02858804 | Institute of Hematology & Blood Diseases Hospital, China | Phase 4 |
| Completed | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mant NCT02633137 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 NCT02507336 | University of Miami | Phase 2 |
| Completed | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients NCT02558816 | Nantes University Hospital | Phase 1 / Phase 2 |
| Terminated | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma NCT02356458 | Swiss Cancer Institute | Phase 1 / Phase 2 |
| Unknown | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) NCT02471391 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Active Not Recruiting | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma NCT02446236 | Hackensack Meridian Health | Phase 1 |
| Active Not Recruiting | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Ce NCT02427620 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligib NCT02267915 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Completed | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL NCT02268851 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Tissue Collection for Biomarkers Determining Resistance to Ibrutinib NCT02267590 | Royal Marsden NHS Foundation Trust | — |
| Completed | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL NCT02142530 | Massachusetts General Hospital | Phase 1 |
| Completed | Safety Study of SGN-CD70A in Cancer Patients NCT02216890 | Seagen Inc. | Phase 1 |
| Unknown | CART-19 Immunotherapy in Mantle Cell Lymphoma NCT02081937 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Ublituximab + Ibrutinib in Select B-cell Malignancies NCT02013128 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With NCT01865110 | The Lymphoma Academic Research Organisation | Phase 3 |
| Recruiting | A Long-term Extension Study of PCI-32765 (Ibrutinib) NCT01804686 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patient NCT01880567 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies NCT01796470 | Gilead Sciences | Phase 2 |
| Completed | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituxim NCT01776840 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Study of LY2835219 for Mantle Cell Lymphoma NCT01739309 | Eli Lilly and Company | Phase 2 |
| Terminated | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapse NCT01799889 | Gilead Sciences | Phase 2 |
| Terminated | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL NCT01728207 | Gilead Sciences | Phase 1 |
| Terminated | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma NCT01685606 | Brown University | Phase 2 |
| Completed | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Re NCT01646021 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912 | TG Therapeutics, Inc. | Phase 1 |
| Terminated | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) NCT01500538 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Completed | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma NCT01652144 | NCIC Clinical Trials Group | Phase 2 |
| Completed | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma NCT01665768 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma NCT01661881 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older NCT01415752 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress A NCT01599949 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL NCT01737177 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | Double Cord Versus Haploidentical (BMT CTN 1101) NCT01597778 | Medical College of Wisconsin | Phase 3 |
| Terminated | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma NCT01578343 | Samsung Medical Center | Phase 2 |
| Unknown | Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) NCT01439750 | Milton S. Hershey Medical Center | Phase 1 |
| Completed | Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy NCT03054883 | Czech Lymphoma Study Group | — |
| Completed | Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With NCT01662050 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Terminated | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma NCT01497275 | Duke University | Phase 2 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Ma NCT01410513 | Sanofi | Phase 1 |
| Completed | Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advance NCT01484093 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers NCT01460134 | Celldex Therapeutics | Phase 1 |
| Completed | Study of Mantle Cell Lymphoma Treatment by RiBVD NCT01457144 | French Innovative Leukemia Organisation | Phase 2 |
| Completed | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem NCT01437709 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincrist NCT01397825 | Millennium Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma NCT01472562 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies NCT01399840 | Pfizer | Phase 1 |
| Completed | Imexon for Relapsed Follicular and Aggressive Lymphomas NCT01314014 | University of Rochester | Phase 2 |
| Completed | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL NCT01562977 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Completed | AMG 319 Lymphoid Malignancy FIH NCT01300026 | Amgen | Phase 1 |
| Completed | Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) NCT01504776 | Anand Jillella | Phase 1 |
| Completed | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) NCT01236391 | Pharmacyclics LLC. | Phase 2 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies NCT01263899 | S*BIO | Phase 2 |
| Completed | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell NCT01239875 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients Wi NCT00992446 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma NCT01111188 | Weill Medical College of Cornell University | Phase 1 |
| Completed | Tandem Auto-Allo Transplant for Lymphoma NCT01181271 | Massachusetts General Hospital | Phase 2 |
| Completed | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy NCT01184885 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Completed | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myelom NCT01148108 | Telik | Phase 2 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Withdrawn | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma NCT01460602 | Louisiana State University Health Sciences Center Shreveport | Phase 1 / Phase 2 |
| Withdrawn | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) NCT01170052 | Charite University, Berlin, Germany | Phase 1 / Phase 2 |
| Unknown | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and AS NCT02354313 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Terminated | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combina NCT01021423 | Celgene | Phase 3 |
| Completed | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti- NCT01088048 | Gilead Sciences | Phase 1 |
| Completed | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma NCT01078142 | Georg Hess, MD | Phase 1 / Phase 2 |
| Completed | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Pati NCT01073163 | Cephalon | Phase 3 |
| Terminated | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma NCT00843050 | Piramal Enterprises Limited | Phase 2 |